Single-centred experience with levosimendan in paediatric decompensated dilated cardiomyopathy

Related Experiment Video

Updated: Apr 15, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
05:18

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

196

Pierre-Emmanuel Séguéla1, Philippe Mauriat2, Jean-Baptiste Mouton1

  • 1Paediatric Cardiology Unit, Bordeaux University Hospital, Bordeaux, France.

Archives of Cardiovascular Diseases
|April 13, 2015
PubMed

Insights

Levosimendan improved hemodynamics in children with advanced heart failure, potentially delaying mechanical support needs while awaiting heart transplants. This inotropic agent is a valuable consideration for pediatric heart failure management.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Pharmacology
  • Heart Failure Management

Background:

  • Children with dilated cardiomyopathy often face prolonged waits for heart transplantation, necessitating mechanical circulatory support.
  • Levosimendan, a positive inotropic agent, shows promise in treating pediatric heart failure.

Purpose of the Study:

  • To evaluate the clinical experience of using levosimendan in pediatric patients with decompensated dilated cardiomyopathy.

Main Methods:

  • Retrospective analysis of pediatric patients with dilated cardiomyopathy awaiting transplantation.
  • Levosimendan infusions administered prior to mechanical circulatory support consideration.
  • Analysis of biological markers (B-type natriuretic peptide) and echocardiographic parameters (ejection fraction, velocity time integral).

Main Results:

  • Significant reduction in B-type natriuretic peptide levels post-infusion (P=0.003).
  • Trend towards improved left ventricular ejection fraction (P=0.054-0.068).
  • Significant increase in subaortic velocity time integral, indicating improved cardiac output (P=0.041).

Conclusions:

  • Levosimendan demonstrates hemodynamic benefits in pediatric decompensated dilated cardiomyopathy.
  • Repeated levosimendan infusions may postpone the need for mechanical circulatory support.
  • Levosimendan should be considered as an adjunct to standard inotropic therapies in this patient population.
Abstract

Keywords:
Brain natriuretic peptideBrain natriurétique peptideCardiomyopathie dilatéeDilated cardiomyopathyInsuffisance cardiaque pédiatriqueLevosimendanPaediatric heart failurePaediatric heart transplantationTransplantation cardiaque pédiatrique

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
909
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
571
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
789
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
707